Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, presented data from the recent Phase Ib trial NCT02332850 at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. This trial explored the impact of CD38-targeting monoclonal antibody isatuximab with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The safety data obtained in this study were in line with expected values, and the efficacy data showed that this combination could be greatly beneficial in heavily pre-treated patient groups.
Promising results for isatuximab with carfilzomib in R/R MM
